HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells

Apoptosis

Volumn 16, Issue 9, 2011, Pages 914-923

  Bodo, Juraj ^a   Sedlak, Jan ^b   MacIejewski, Jaroslaw P ^c   Almasan, Alex ^a   Hsi, Eric D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Enzastaurin; Histone deacetylase inhibitors; Lymphoma cells; Synergy

Indexed keywords

6 (4 CHLOROPHENYLSULFANYL) 2,4 HEXADIENOIC ACID HYDROXYAMIDE; ENZASTAURIN; HISTONE DEACETYLASE INHIBITOR; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LEUKEMIA CELL; LYMPHOMA CELL; PRIORITY JOURNAL; T CELL LYMPHOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASE 7; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FLUORESCENT ANTIBODY TECHNIQUE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; LYMPHOMA; SULFIDES; TUMOR SUPPRESSOR PROTEIN P53; VALPROIC ACID;

EID: 80052509007     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-011-0617-x     Document Type: Article

References (40)

1. K Podar MS Raab D Chauhan KC Anderson 2007 The therapeutic role of targeting protein kinase C in solid and hematologic malignancies Expert Opin Investig Drugs 16 1693 1707 17922632 10.1517/13543784.16.10.1693 1:CAS:528:DC%2BD2sXhtFekt7jE (Pubitemid 350030716)
2. AC Spalding BD Zeitlin K Wilder-Romans ME Davis JE Nor TS Lawrence E Ben-Josef 2008 Enzastaurin, an inhibitor of PKCbeta, enhances antiangiogenic effects and cytotoxicity of radiation against endothelial cells Transl Oncol 1 195 201 19043530
3. K Brautigam DO Bauerschlag MT Weigel J Biernath-Wupping T Bauknecht N Arnold N Maass I Meinhold-Heerlein 2009 Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation Transl Oncol 2 164 173 19701501
4. C Tekle E Giovannetti J Sigmond JR Graff K Smid GJ Peters 2008 Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells Br J Cancer 99 750 759 18728666 10.1038/sj.bjc.6604566 1:CAS:528: DC%2BD1cXhtVGgtb7K
5. P Bali P George P Cohen J Tao F Guo C Sigua A Vishvanath A Scuto S Annavarapu W Fiskus L Moscinski P Atadja K Bhalla 2004 Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3 Clin Cancer Res 10 4991 4997 15297399 10.1158/1078-0432.CCR-04-0210 1:CAS:528:DC%2BD2cXmtlSitrs%3D (Pubitemid 39099772)
6. UM Vogl W Berger M Micksche C Pirker W Lamm O Pichelmeyer CC Zielinski M Schmidinger 2009 Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines Cancer Lett 277 218 226 19171421 10.1016/j.canlet.2008.12.013 1:CAS:528:DC%2BD1MXjslOkur8%3D
7. F Morgillo E Martinelli T Troiani G Laus S Pepe C Gridelli F Ciardiello 2008 Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells Mol Cancer Ther 7 1698 1707 18566241 10.1158/1535-7163.MCT-07-0547 1:CAS:528:DC%2BD1cXnsVSkuro%3D
8. AS Moreau X Jia HT Ngo X Leleu G O'Sullivan Y Alsayed A Leontovich K Podar J Kutok J Daley S Lazo-Kallanian E Hatjiharissi MS Raab L Xu SP Treon T Hideshima KC Anderson IM Ghobrial 2007 Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia Blood 109 4964 4972 17284528 10.1182/blood-2006-10-054577 1:CAS:528: DC%2BD2sXmt1Onsrw%3D (Pubitemid 46827795)
9. JR Graff AM McNulty KR Hanna BW Konicek RL Lynch SN Bailey C Banks A Capen R Goode JE Lewis L Sams KL Huss RM Campbell PW Iversen BL Neubauer TJ Brown L Musib S Geeganage D Thornton 2005 The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts Cancer Res 65 7462 7469 16103100 10.1158/0008-5472.CAN- 05-0071 1:CAS:528:DC%2BD2MXns1Wqsrc%3D (Pubitemid 41161281)
10. AC Spalding R Watson ME Davis AC Kim TS Lawrence E Ben-Josef 2007 Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer Clin Cancer Res 13 6827 6833 18006785 10.1158/1078-0432.CCR-07-0454 1:CAS:528:DC%2BD2sXhtlSmu7fF (Pubitemid 350206821)
11. JG Herman SB Baylin 2003 Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 349 2042 2054 14627790 10.1056/NEJMra023075 1:CAS:528:DC%2BD3sXptFKmu7s%3D (Pubitemid 37448928)
12. J Chen W Fiskus K Eaton P Fernandez Y Wang R Rao P Lee R Joshi Y Yang R Kolhe R Balusu P Chappa K Natarajan A Jillella P Atadja KN Bhalla 2009 Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism Blood 113 4038 4048 19074726 10.1182/blood-2008-08-176024 1:CAS:528:DC%2BD1MXlsVWrsbY%3D
13. KB Glaser 2007 HDAC inhibitors: clinical update and mechanism-based potential Biochem Pharmacol 74 659 671 17498667 10.1016/j.bcp.2007.04.007 1:CAS:528:DC%2BD2sXotlajsr8%3D (Pubitemid 47096639)
14. M Ocker A Alajati M Ganslmayer S Zopf M Luders D Neureiter EG Hahn D Schuppan C Herold 2005 The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells J Cancer Res Clin Oncol 131 385 394 15754201 10.1007/s00432-004-0664-6 1:CAS:528:DC%2BD2MXjs1OlsLY%3D (Pubitemid 40674624)
15. S Bhalla S Balasubramanian K David M Sirisawad J Buggy L Mauro S Prachand R Miller LI Gordon AM Evens 2009 PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells Clin Cancer Res 15 3354 3365 19417023 10.1158/1078-0432.CCR-08-2365 1:CAS:528:DC%2BD1MXmtVKmurc%3D
16. HC Drexler M Euler 2005 Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis Apoptosis 10 743 758 16133866 10.1007/s10495-005-2942-4 1:CAS:528:DC%2BD2MXotFentb0%3D (Pubitemid 41187074)
17. CK Lee S Wang X Huang J Ryder B Liu 2010 HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells Cancer Lett 296 233 240 20447761 10.1016/j.canlet.2010.04.014 1:CAS:528:DC%2BC3cXpsFOqurc%3D
18. M Rahmani E Reese Y Dai C Bauer SG Payne P Dent S Spiegel S Grant 2005 Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species Cancer Res 65 2422 2432 15781658 10.1158/0008-5472.CAN-04-2440 1:CAS:528: DC%2BD2MXisFGns7c%3D (Pubitemid 40490154)
19. N Goode K Hughes JR Woodgett PJ Parker 1992 Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes J Biol Chem 267 16878 16882 1324914 1:CAS:528:DyaK38Xmt1yru7c%3D
20. J Bodo L Durkin ED Hsi 2009 Quantitative in situ detection of phosphoproteins in fixed tissues using quantum dot technology J Histochem Cytochem 57 701 708 19332430 10.1369/jhc.2009.953547 1:CAS:528: DC%2BD1MXnsVSrtbY%3D
21. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 6382953 10.1016/0065-2571(84)90007-4 1:CAS:528: DyaL2cXktlaksLk%3D
22. HS Mellert TJ Stanek SM Sykes FJ Rauscher III DC Schultz SB McMahon 2011 Deacetylation of the DNA-binding domain regulates p53-mediated apoptosis J Biol Chem 286 4264 4270 21148320 10.1074/jbc.M110.184663 1:CAS:528: DC%2BC3MXhsFGltr8%3D
23. SE Aeder PM Martin JW Soh IM Hussaini 2004 PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways Oncogene 23 9062 9069 15489897 10.1038/sj.onc.1208093 1:CAS:528:DC%2BD2cXhtVehtbzI (Pubitemid 40013073)
24. A Balendran GR Hare A Kieloch MR Williams DR Alessi 2000 Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms FEBS Lett 484 217 223 11078882 10.1016/S0014-5793(00)02162-1 1:CAS:528:DC%2BD3cXotVCkur0%3D
25. Y Kawakami H Nishimoto J Kitaura M Maeda-Yamamoto RM Kato DR Littman M Leitges DJ Rawlings T Kawakami 2004 Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion J Biol Chem 279 47720 47725 15364915 10.1074/jbc.M408797200 1:CAS:528: DC%2BD2cXptl2gu7s%3D (Pubitemid 39540919)
26. C Partovian M Simons 2004 Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells Cell Signal 16 951 957 15157674 10.1016/j.cellsig.2004.01.008 1:CAS:528: DC%2BD2cXkt1Srsr8%3D (Pubitemid 38638784)
27. X Fang S Yu JL Tanyi Y Lu JR Woodgett GB Mills 2002 Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway Mol Cell Biol 22 2099 2110 11884598 10.1128/MCB.22.7.2099-2110.2002 1:CAS:528:DC%2BD38Xit1KisbY%3D (Pubitemid 34224618)
28. PJ Morin AB Sparks V Korinek N Barker H Clevers B Vogelstein KW Kinzler 1997 Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC Science 275 1787 1790 9065402 10.1126/science.275.5307.1787 1:CAS:528:DyaK2sXitVGrtL0%3D (Pubitemid 27136715)
29. A Damalas A Ben-Ze'Ev I Simcha M Shtutman JF Leal J Zhurinsky B Geiger M Oren 1999 Excess beta-catenin promotes accumulation of transcriptionally active p53 EMBO J 18 3054 3063 10357817 10.1093/emboj/18.11.3054 1:CAS:528: DyaK1MXktFCjtbw%3D (Pubitemid 29255614)
30. K Kim KM Pang M Evans ED Hay 2000 Overexpression of beta-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators Mol Biol Cell 11 3509 3523 11029052 1:CAS:528:DC%2BD3cXnslWntLw%3D
31. MS Raab I Breitkreutz G Tonon J Zhang PJ Hayden T Nguyen JH Fruehauf BK Lin D Chauhan T Hideshima NC Munshi KC Anderson K Podar 2009 Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling Blood 113 1513 1521 19018094 10.1182/blood-2008-05-157040 1:CAS:528:DC%2BD1MXitlCrtLY%3D
32. J Gwak M Cho SJ Gong J Won DE Kim EY Kim SS Lee M Kim TK Kim JG Shin S Oh 2006 Protein-kinase-C-mediated beta-catenin phosphorylation negatively regulates the Wnt/beta-catenin pathway J Cell Sci 119 4702 4709 17093267 10.1242/jcs.03256 1:CAS:528:DC%2BD2sXkt1Sn (Pubitemid 44964266)
33. O Tetsu F McCormick 1999 Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells Nature 398 422 426 10201372 10.1038/18884 1:CAS:528:DyaK1MXisFGksrY%3D (Pubitemid 29180374)
34. AN Billin H Thirlwell DE Ayer 2000 Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator Mol Cell Biol 20 6882 6890 10958684 10.1128/MCB.20.18.6882-6890. 2000 1:CAS:528:DC%2BD3cXmsVamsL0%3D
35. R Kristeleit L Stimson P Workman W Aherne 2004 Histone modification enzymes: novel targets for cancer drugs Expert Opin Emerg Drugs 9 135 154 15155140 10.1517/14728214.9.1.135 1:CAS:528:DC%2BD2cXkt1Ggt7Y%3D (Pubitemid 38715582)
36. MV Blagosklonny R Robey DL Sackett L Du F Traganos Z Darzynkiewicz T Fojo SE Bates 2002 Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity Mol Cancer Ther 1 937 941 12481415 1:CAS:528:DC%2BD3sXmvFOntg%3D%3D
37. X Yu ZS Guo MG Marcu L Neckers DM Nguyen GA Chen DS Schrump 2002 Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228 J Natl Cancer Inst 94 504 513 11929951 1:CAS:528:DC%2BD38Xjt1Ciur8%3D (Pubitemid 34411289)
38. M Saegusa M Hashimura T Kuwata M Hamano I Okayasu 2004 Beta-catenin simultaneously induces activation of the p53-p21WAF1 pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells Am J Pathol 164 1739 1749 15111320 10.1016/S0002-9440(10)63732-7 1:CAS:528:DC%2BD2cXns1Gqu7s%3D (Pubitemid 38529776)
39. WK Kelly OA O'Connor LM Krug JH Chiao M Heaney T Curley B MacGregore-Cortelli W Tong JP Secrist L Schwartz S Richardson E Chu S Olgac PA Marks H Scher VM Richon 2005 Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J Clin Oncol 23 3923 3931 15897550 10.1200/JCO.2005.14.167 1:CAS:528: DC%2BD2MXmtVahtLw%3D (Pubitemid 46218695)
40. MA Carducci L Musib MS Kies R Pili M Truong JR Brahmer P Cole R Sullivan J Riddle J Schmidt N Enas V Sinha DE Thornton RS Herbst 2006 Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer J Clin Oncol 24 4092 4099 16943527 10.1200/JCO.2005.05.3447 1:CAS:528:DC%2BD28XhtVantb3K (Pubitemid 46622284)